Get the Stockscreener App
0.2715
1.50%
0.004
After Hours:
.27
-0.0015
-0.55%
Syros Pharmaceuticals Inc stock is traded at $0.2715, with a volume of 1.73M.
It is up +1.50% in the last 24 hours and down -89.27% over the past month.
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.
See More
Previous Close:
$0.2675
Open:
$0.2675
24h Volume:
1.73M
Relative Volume:
0.23
Market Cap:
$7.29M
Revenue:
$9.94M
Net Income/Loss:
$-144.49M
P/E Ratio:
-0.0485
EPS:
-5.5956
Net Cash Flow:
$-103.90M
1W Performance:
-7.40%
1M Performance:
-89.27%
6M Performance:
-94.62%
1Y Performance:
-90.13%
1-Day Range:
$0.2607
$0.2793
1-Week Range:
$0.2361
$0.2989
52-Week Range:
$0.183
$8.17
Syros Pharmaceuticals Inc Stock (SYRS) Company Profile
Name
Syros Pharmaceuticals Inc
Sector
Industry
Phone
617-744-1340
Address
35 CAMBRIDGE PARK DRIVE, CAMBRIDGE
Compare SYRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SYRS
Syros Pharmaceuticals Inc
|
0.2715 | 7.29M | 9.94M | -144.49M | -103.90M | -5.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Syros Pharmaceuticals Inc Stock (SYRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| Jan-17-20 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-08-19 | Resumed | JMP Securities | Mkt Outperform |
| Feb-14-19 | Resumed | Oppenheimer | Outperform |
| Nov-05-18 | Upgrade | ROTH Capital | Neutral → Buy |
| Mar-13-18 | Reiterated | Wedbush | Outperform |
| Oct-31-17 | Resumed | Piper Jaffray | Overweight |
| Oct-23-17 | Initiated | ROTH Capital | Neutral |
| Aug-10-17 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
View All
Syros Pharmaceuticals Inc Stock (SYRS) Latest News
Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by StockNews.com - Defense World
SYRS (Syros Pharmaceuticals) 9-Day RSI : 26.16 (As of Nov. 24, 2024) - GuruFocus.com
Syros cut to neutral by H.C. Wainwright on failed drug study - MSN
Syros pharmaceuticals chief development officer sells shares for $7,949 - Investing.com India
Syros pharmaceuticals chief medical officer sells shares for $2,382 By Investing.com - Investing.com Australia
Syros Pharmaceuticals chief legal officer sells $10,320 in stock By Investing.com - Investing.com Australia
Syros pharmaceuticals chief medical officer sells shares for $2,382 - Investing.com India
Syros Pharmaceuticals CEO Chee Conley sells shares worth $26,932 By Investing.com - Investing.com Canada
Syros Pharmaceuticals CEO Chee Conley sells shares worth $26,932 - Investing.com
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2024 Earnings Call Transcript - MSN
Syros downgraded to Market Perform from Outperform at JMP Securities - MSN
Brookline Capital Downgrades Syros Pharmaceuticals (SYRS) - MSN
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal - MSN
Syros Pharmaceuticals hits record low on QIAGEN deal termination and leadership changes - XM
Syros Pharmaceuticals announces major company changes - Investing.com
Syros Pharmaceuticals announces major company changes By Investing.com - Investing.com UK
Syros Pharmaceuticals Faces Financial Struggles Amid Key Challenges - TipRanks
What is HC Wainwright’s Forecast for SYRS Q1 Earnings? - Defense World
Avidity Partners Management LP's Strategic Acquisition in Syros Pharmaceuticals Inc - GuruFocus.com
Blue Owl Capital Holdings LP Increases Stake in Syros Pharmaceuticals Inc - GuruFocus.com
Syros Pharmaceuticals (NASDAQ:SYRS) Earns Neutral Rating from HC Wainwright - Defense World
Syros Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright - Yahoo Finance
JMP Securities cuts Syros Pharma stock rating following unsuccessful trial By Investing.com - Investing.com Australia
Syros Pharmaceuticals' SWOT analysis: stock faces headwinds after trial setback - Investing.com Canada
No RARA, Syros trouble: MDS phase III sinks tamibarotene - BioWorld Online
Syros’s Hopes Dashed As Tamibarotene Flunks Phase III MDS Trial - Citeline News & Insights
Syros Pharmaceuticals stock hits 52-week low at $0.4 By Investing.com - Investing.com Canada
JMP Securities cuts Syros Pharma stock to Market Perform - Investing.com
U.S. Stock market: Syros Pharmaceuticals(−86.21%), GlucoTrack(−77.70%) and others among the most volatile stocks during mid day trading - Business Upturn
Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default - Benzinga
Syros Pharmaceuticals downgraded to Hold from Buy at TD Cowen - TipRanks
Syros Pharmaceuticals stock hits 52-week low at $0.4 - Investing.com
Syros stock craters after lead cancer therapy flops in Phase III trial - Pharmaceutical Technology
U.S. Stock market: Syros Pharmaceuticals surges by 680.00% while Spirit Airlines rises by 184.96% in early trading - Business Upturn
Syros flunks phase 3 blood cancer trial, triggering loan default and share-price plunge - Fierce Biotech
Syros Pharmaceuticals' (SYRS) Hold Rating Reiterated at Brookline Capital Management - MarketBeat
Analysts Set Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Target Price at $5.00 - MarketBeat
JMP Securities Reiterates Market Perform Rating for Syros Pharmaceuticals (NASDAQ:SYRS) - MarketBeat
Syros Pharmaceuticals' (SYRS) "Hold" Rating Reaffirmed at TD Cowen - MarketBeat
Syros Pharmaceuticals Shares Plummet Premarket After Study Failure - MarketWatch
Syros Crashes Over 90% on Late-Stage MDS Fail, Loan Default - BioSpace
TD Cowen downgrades Syros Pharma stock to Hold on trial failure - Investing.com
Syros stock dives 92% on failed Phase 3 study, possible loan default (update) - MSN
Syros Pharmaceuticals trial fails to meet primary goal - Investing.com
Syros Pharmaceuticals trial fails to meet primary goal By Investing.com - Investing.com UK
Syros Pharma Stock Alert: Phase 3 Trial Fails, Loan Default Triggered | SYRS Stock News - StockTitan
Syros Pharmaceuticals (NASDAQ:SYRS) Rating Lowered to Sell at StockNews.com - MarketBeat
SYRS (Syros Pharmaceuticals) Total Inventories : $0.00 Mil (As of Sep. 2024) - GuruFocus.com
Syros Pharmaceuticals, Inc. announced that it expects to receive $10 million in funding from Incyte Corporation - Marketscreener.com
Incyte Corporation and yros Pharmaceuticals Announce Global Target Discovery and Validation Collaboration Focused on Myeloproliferative Neoplasms - Marketscreener.com
Syros Pharmaceuticals Inc Stock (SYRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):